Experimental Gene-Silencing Drug BIIB094 Shows Promise in First Parkinson's Disease Trial
核心洞察
BIIB094, an experimental antisense oligonucleotide therapy targeting LRRK2 (搜索), safely reduced protein levels by up to 59% in cerebrospinal fluid of Parkinson's patients in a phase 1 trial.
The randomized, placebo-controlled study of 82 participants demonstrated good tolerability with no serious adverse events related to the treatment.
Results suggest the therapy could potentially benefit a broader Parkinson's population beyond those with confirmed LRRK2 (搜索) genetic variants.
An experimental gene-silencing therapy has achieved a significant milestone in Parkinson's disease (搜索) research, successfully reducing levels of a key disease-linked protein in the first human trial of its kind. The treatment, BIIB094, targets LRRK2 (搜索), the most common genetic contributor to Parkinson's disease, which affects nearly 10 million people worldwide.
The phase 1 randomized, placebo-controlled trial, published in Nature Medicine, enrolled 82 participants with Parkinson's disease (搜索) across two study segments. The primary objective was to evaluate safety rather than clinical efficacy, according to study co-author Dr. Danielle Larson, assistant professor in Northwestern University's Division of Movement Disorders.
"This was a multi-center clinical trial looking at an antisense oligonucleotide therapy for LRRK2 (搜索)-specific Parkinson's disease (搜索)," Larson explained. "The main goal was to examine the safety of delivering this therapy to patients, with the hope that if it proved safe, future studies could evaluate whether it might slow disease progression."
Trial Design and Safety Profile
The study was conducted in two parts. In the first segment, 40 participants received either a single dose of BIIB094 or placebo. The second segment involved 42 participants who received four doses of the drug or placebo, administered every four weeks. The therapy was delivered intrathecally, meaning directly into the cerebrospinal fluid through lumbar puncture.
Participants in the second part were stratified based on whether they carried a known LRRK2 (搜索) genetic variant, allowing researchers to assess the treatment's effects across different genetic backgrounds.
The treatment demonstrated a favorable safety profile across both trial segments. While adverse events were common, they were predominantly mild to moderate in severity and did not prevent continued dosing. Importantly, no serious adverse events related to BIIB094 were reported throughout the study.
Significant Protein Reduction Achieved
Beyond establishing safety, the trial provided compelling evidence that BIIB094 successfully engaged its intended biological target. Analysis of cerebrospinal fluid revealed that LRRK2 (搜索) protein levels dropped by as much as 59% in treated participants compared to placebo.
"The antisense oligonucleotide was designed specifically to reduce LRRK2 (搜索) expression," Larson noted. "Because overactivity of this protein kinase is thought to be part of the problem in Parkinson's disease (搜索), reducing LRRK2 levels could be protective and potentially modify the disease."
Notably, these protein reductions occurred regardless of whether patients carried a known LRRK2 (搜索) mutation, suggesting the therapy might eventually benefit a broader Parkinson's population beyond those with confirmed genetic diagnoses.
Targeting Disease Biology
The findings represent a potential shift toward addressing the underlying biology of Parkinson's disease (搜索) rather than merely treating symptoms. Researchers have long theorized that reducing LRRK2 (搜索) activity could help slow or alter the disease course, but translating this concept into practical therapy has proven challenging.
"The new findings hint at a possible mechanism by which LRRK2 (搜索)-targeting therapies could influence the underlying disease process, rather than simply addressing symptoms," Larson said.
Next Steps and Clinical Implications
While the results are encouraging, Larson emphasized that the trial was not designed to assess clinical benefits such as improvements in movement, cognition, or disease progression. The next phase of research will require larger, longer-duration studies to determine whether LRRK2 (搜索) reduction translates into meaningful patient outcomes.
"The next step would be a phase 2 study with a larger group of patients," Larson explained. "Instead of focusing only on safety, those trials would look at efficacy, whether the therapy can slow disease progression using motor assessments and standard Parkinson's rating scales."
Advancing Precision Medicine
The study marks an important milestone in the development of targeted Parkinson's treatments and validates the antisense oligonucleotide approach for neurological disorders.
"This is one of the first antisense oligonucleotide, or ASO, therapies in Parkinson's disease (搜索) to have safety and tolerability data," Larson said. "It really paves the way for other ASO-based treatments to be developed, potentially targeting different biological pathways."
The research was funded by Biogen, which developed BIIB094 as part of its neurodegenerative disease portfolio. The successful completion of this phase 1 trial positions the therapy for advancement into larger efficacy studies that could ultimately determine its potential as a disease-modifying treatment for Parkinson's disease (搜索).